Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer With Intracranial Metastases
Interventions: DRUG: cabazitaxel|DRUG: lapatinib
Sponsor: SCRI Development Innovations, LLC
Collaborators: Novartis|GlaxoSmithKline|Sanofi